There is a profound mismatch between the critical role of diagnostics in guiding medical treatment and their reimbursement value. This value gap highlights a systemic inefficiency and a major opportunity for companies that can demonstrate improved patient outcomes and system-wide savings.

Many product launch failures are not due to weak science but to a disconnect between the optimistic narrative sold to investors and the actual product profile handed to the commercial team. This expectation gap, created during fundraising, sets the stage for perceived failure upon launch.

Startup revenue projections often rely on signed distribution agreements that can rapidly evaporate under media scrutiny. Theranos missed its revenue targets because Walgreens defaulted on an 800-store rollout contract following adverse press, converting contractual projections into accusations of fabricated financial metrics.

Guardant's co-CEO argues that in complex fields like diagnostics, success hinges more on innovating the business model than the core technology. Superior tech fails if it doesn't align with the unique economic incentives where the user isn't the payer.

Despite operating over 12 million diagnostic tests, federal prosecutors failed to convict Elizabeth Holmes of patient harm after presenting only four patient testimonies. The jury acquitted her of patient fraud, finding her guilty strictly on investor fraud and conspiracy charges.

Many companies fail by building a technology and then searching for a problem. VedaBio exemplifies the opposite approach: first defining the "perfect product" for a specific need (urgent care testing), and then applying the right technology to build it.

Early-stage biotech investing is less about quantitative analysis, as companies lack cash flow for traditional valuation. The primary skill is identifying founders who lack deep domain expertise, citing Y Combinator founders who didn't understand the CPT billing codes their company was based on.

Nikita Beer argued Holmes was created in the 2011-2015 TED-talk entrepreneur era, when child prodigies and accelerators were celebrated and fudged studies were excused as fake-it-till-you-make-it. Holmes kept running that playbook in medical technology after the era ended, and got caught only when the world woke up.

Regulatory approval is just an early milestone in diagnostics. True success requires solving for reimbursement, manufacturing scale, supply chain, and commercialization from the very beginning. These non-scientific hurdles are critical for building a viable business.